NEW YORK, Nov. 27, 2018 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. reminds investors that class action
lawsuits have been commenced on behalf of stockholders of Applied Optoelectronics, Inc., Acadia Healthcare Company, Inc., and TG
Therapeutics, Inc. Stockholders have until the deadlines listed below to petition the court to serve as lead plaintiff.
Additional information about each case can be found at the link provided.
Applied Optoelectronics, Inc. (NASDAQ: AAOI)
Class Period: August 7, 2018 - September 27, 2018
Lead Plaintiff Deadline: November 30, 2018
The Complaint alleges that, throughout the Class Period, defendants made materially false and/or misleading
statements, as well as failed to disclose material adverse facts about the company’s business, operations, and prospects.
Specifically, defendants failed to disclose to investors: (1) that certain of the company’s lasers were susceptible to fail
prematurely; (2) that certain of the company’s transceivers utilizing these lasers would be materially affected; and (3) that, as a
result of the foregoing, defendant’s positive statements about the company’s business, operations, and prospects, were materially
misleading and/or lacked a reasonable basis.
To learn more about the AAOI class action go to: http://bespc.com/aaoi/.
Acadia Healthcare Company, Inc. (NASDAQ: ACHC)
Class Period: February 23, 2017 - October 24, 2017
Lead Plaintiff Deadline: December 3, 2018
The complaint alleges that throughout the Class Period, defendants made materially false and misleading
statements regarding Acadia’s business and operations, including by falsely stating that the quality of Acadia’s U.K. operations
gave it a competitive strength that would drive future growth and profitability, and by issuing false and misleading guidance
regarding the company’s actual and projected 2017 revenue, earnings before interest, taxes, depreciation and amortization and
earnings per share.
To learn more about the Acadia class action go to: http://bespc.com/acad/.
TG Therapeutics, Inc. (NASDAQ: TGTX)
Class Period: June 4, 2018 - September 25, 2018
Lead Plaintiff Deadline: December 3, 2018
The complaint alleges that throughout the Class Period, defendants made false and misleading statements and/or
failed to disclose adverse information regarding TG’s business and prospects. Specifically, the complaint alleges defendants
failed to disclose that: (1) TG was involved in cleaning the data collected in the UNITY-CLL Trial; and (2) as a result, was able
to gain an understanding as to the efficacy of the combination therapy; (3) as a result of that data cleaning, TG knew the
UNITY-CLL Trial had failed to meet its stated goal; and (4) as a result, the company would not be able to seek accelerated
approval; and that, given that the UNITY-CLL Trial had failed to meet its stated goal, it was highly unlikely that the combination
therapy would meet its primary endpoint of increased progression free survival.
To learn more about the TGTX class action go to: https://bespc.com/tgtx/.
Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities
litigation. For additional information about Bragar Eagel & Squire, P.C. please go to www.bespc.com. Attorney advertising. Prior results do not guarantee similar
outcomes.
Contacts
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com
